Literature DB >> 15647953

Comparison of clinical, magnetic resonance and evoked potentials data in a case of valproic-acid-related hyperammonemic coma.

Philippe Hantson1, Cécile Grandin, Thierry Duprez, Marie-Cécile Nassogne, Jean-Michel Guérit.   

Abstract

Magnetic resonance (MR) multimodality evoked potentials (MEPs) and clinical findings were correlated in a 47-year-old epileptic man in whom parenteral valproic acid (VPA) therapy induced severe comatose hyperammonemic encephalopathy without biological signs of hepatotoxicity (or hepatocytic dysfunction). Although the plasma VPA level remained within a normal therapeutic range, the ammoniemia increased to a toxic peak level at 411 micromol/l 24 h after symptom onset, requiring VPA therapy discontinuation. Brain MR monitoring demonstrated early cytotoxic edema evolving into delayed vasogenic edema and final brain atrophy. Concomitantly to abnormalities within the brainstem on MR images, an increase in brainstem conduction at MEPs and clinical disturbance of brainstem reflexes were observed at the initial phase of the disease course. Later, the resolution of the MR and MEPs abnormalities paralleled the clinical recovery of the reflexes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15647953     DOI: 10.1007/s00330-004-2338-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  25 in total

Review 1.  Magnetic resonance imaging measurement of brain edema in patients with liver disease: resolution after transplantation.

Authors:  Alex Rovira; Juan Córdoba; Nuria Raguer; Juli Alonso
Journal:  Curr Opin Neurol       Date:  2002-12       Impact factor: 5.710

2.  Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.

Authors:  H M Hamer; S Knake; U Schomburg; F Rosenow
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

3.  Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure.

Authors:  W J Triggs; R L Gilmore; D S Millington; J Cibula; T S Bunch; E Harman
Journal:  Int J Clin Pharmacol Ther       Date:  1997-09       Impact factor: 1.366

4.  Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites.

Authors:  R E Dupuis; S N Lichtman; G M Pollack
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

5.  MRI in a case of adult-onset citrullinemia.

Authors:  Y F Chen; Y C Huang; H M Liu; W L Hwu
Journal:  Neuroradiology       Date:  2001-10       Impact factor: 2.804

6.  Valproic acid-induced hyperammonemic encephalopathy: MR appearance.

Authors:  M D Baganz; P E Dross
Journal:  AJNR Am J Neuroradiol       Date:  1994-10       Impact factor: 3.825

7.  Multicenter case series of valproic acid ingestion: serum concentrations and toxicity.

Authors:  H A Spiller; E P Krenzelok; W Klein-Schwartz; M L Winter; J A Weber; D R Sollee; S A Bangh; J R Griffith
Journal:  J Toxicol Clin Toxicol       Date:  2000

8.  Severe cerebral damage in ornithine transcarbamylase deficiency.

Authors:  C L Dolman; R A Clasen; K Dorovini-Zis
Journal:  Clin Neuropathol       Date:  1988 Jan-Feb       Impact factor: 1.368

9.  A case of severe hyperammonemia and unconsciousness following sodium valproate intoxication.

Authors:  W L Lee; C C Yang; J F Deng; Y F Chen; H D Lin; P H Wang
Journal:  Vet Hum Toxicol       Date:  1998-12

10.  Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy.

Authors:  Sargon Ziyeh; Thorsten Thiel; Joachim Spreer; Joachim Klisch; Martin Schumacher
Journal:  Epilepsia       Date:  2002-09       Impact factor: 5.864

View more
  2 in total

Review 1.  Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?

Authors:  Philippe E R Lheureux; Andrea Penaloza; Soheil Zahir; Mireille Gris
Journal:  Crit Care       Date:  2005-06-10       Impact factor: 9.097

2.  Pronounced reversible hyperammonemic encephalopathy associated with combined valproate-topiramate therapy in a 7-year-old girl.

Authors:  Sebastian Weise; Steffen Syrbe; Matthias Preuss; Astrid Bertsche; Andreas Merkenschlager; Matthias K Bernhard
Journal:  Springerplus       Date:  2015-06-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.